Medigen Vaccine Biologics (6547) - Total Liabilities
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has total liabilities worth NT$1.21 Billion TWD (≈ $37.98 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Medigen Vaccine Biologics to evaluate the company's liquid asset resilience ratio.
Medigen Vaccine Biologics - Total Liabilities Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 6547 total assets.
Medigen Vaccine Biologics Competitors by Total Liabilities
The table below lists competitors of Medigen Vaccine Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
Turkey | TL4.69 Billion |
|
SNP Schneider-Neureither & Partner SE
XETRA:SHF
|
Germany | €157.72 Million |
|
Zhongbai Holdings Group Co Ltd
SHE:000759
|
China | CN¥8.22 Billion |
|
Enovix Corp
NASDAQ:ENVX
|
USA | $616.61 Million |
|
Envela Corp
NYSE MKT:ELA
|
USA | $32.07 Million |
|
Luyan Pharma Co Ltd
SHE:002788
|
China | CN¥9.95 Billion |
|
Haoxiangni Jujube Co Ltd
SHE:002582
|
China | CN¥1.40 Billion |
|
Ciputra Development Tbk
JK:CTRA
|
Indonesia | Rp18.34 Trillion |
Liability Composition Analysis (2012–2025)
This chart breaks down Medigen Vaccine Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Medigen Vaccine Biologics to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medigen Vaccine Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual total liabilities of Medigen Vaccine Biologics from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$454.64 Million ≈ $14.32 Million |
-11.53% |
| 2024-12-31 | NT$513.92 Million ≈ $16.19 Million |
-77.12% |
| 2023-12-31 | NT$2.25 Billion ≈ $70.76 Million |
-3.13% |
| 2022-12-31 | NT$2.32 Billion ≈ $73.05 Million |
+272.21% |
| 2021-12-31 | NT$622.95 Million ≈ $19.63 Million |
+78.29% |
| 2020-12-31 | NT$349.40 Million ≈ $11.01 Million |
-61.62% |
| 2019-12-31 | NT$910.28 Million ≈ $28.68 Million |
+59.39% |
| 2018-12-31 | NT$571.10 Million ≈ $17.99 Million |
-7.20% |
| 2017-12-31 | NT$615.41 Million ≈ $19.39 Million |
+76.89% |
| 2016-12-31 | NT$347.90 Million ≈ $10.96 Million |
+12.52% |
| 2015-12-31 | NT$309.19 Million ≈ $9.74 Million |
+127.43% |
| 2014-12-31 | NT$135.95 Million ≈ $4.28 Million |
+598.49% |
| 2013-12-31 | NT$19.46 Million ≈ $613.19K |
-12.13% |
| 2012-12-31 | NT$22.15 Million ≈ $697.85K |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more